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Latent T cellHIV integration predominantly occurs in introns of transcriptionally active genes. To study the impact of the
integration site on HIV gene expression, a complete HIV-1 provirus (with GFP as a fusion with Nef) was
inserted into bacterial artiﬁcial chromosomes (BACs) at three sites previously identiﬁed in latent T cells of
patients: topoisomerase II (Top2A), DNAmethyltransferase 1 (DNMT1), or basic leucine transcription factor 2
(BACH2). Transfection of BAC-HIV into 293 T cells resulted in a fourfold difference in production of infectious
HIV-1. Cell lines were established that contained BAC–Top2A, BAC–DNMT1, or BAC–BACH2, but only BAC–
DNMT1 spontaneously produced virus, albeit at a low level. Stimulation with TNF-α resulted in virus
production from four of ﬁve BAC–Top2A and all BAC–DNMT1 cell lines, but not from the BAC–BACH2 lines.
The results of these studies highlight differences between integration sites identiﬁed in latent T cells to
support virus production and reactivation from latency.l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The use of highly active anti-retroviral therapy (HAART) has
greatly increased the survival of patients with HIV. Through the use of
HAART, viral loads within these HIV-infected individuals have been
controlled to levels below the threshold of detection. However, the
cessation of HAART therapy results in the re-emergence of latent
viruses in these patients (Chun et al., 1997; Han et al., 2007; Richman
et al., 2009). The next step in the management of HIV-infected
patients on HAART will be to devise methodologies in which to coax
out the latently infected virus from cells, which has been proven to be
a challenge due to the complexity of HIV latency (Richman et al.,
2009).
Much of the molecular complexity of HIV latency is due to the
nature of the proviral integration site. Using in vitro infected cells,
previous studies have utilized PCR to identify over 40,000 integration
sites for HIV within the human genome (Wang et al., 2007). From this
analysis and others, HIV was found to predominantly integrate into
actively transcribed genes, mainly in introns (Brady et al., 2009;
Bushman et al., 2005; Lewinski et al., 2005; Wang et al., 2007).
Although a few clusters of integration sites within the human
chromosome were identiﬁed, no speciﬁc sites were found to be
common for HIV integration. Two studies have identiﬁed integration
sites from latently infected T cells isolated directly from patients on
HAART (Han et al., 2004; Ikeda et al., 2007). Consistent with the invitro infection studies, the majority of these integration sites from
latent T cells were found in actively transcribed genes, mainly within
introns (Han et al., 2004; Ikeda et al., 2007). Since the procedure used
to identify these integration sites involved ligation-assisted inverse
PCR, it was not possible to determine whether or not full-length
proviruses were present at the sites (Han et al., 2004; Ikeda et al.,
2007). To fully understand the molecular features of HIV latency, it
will be necessary to unequivocally determine whether or not full-
length HIV proviruses would produce virus if positioned at these sites.
To address this question, we have utilized bacterial artiﬁcial
chromosomes (BACs), since previous studies have shown that the size
of BACs are large enough to contain many of the elements involved in
proper expression of genes encoded within these BACs (Giraldo and
Montoliu, 2001; Schubeler et al., 1998; Testa et al., 2003; Vintersten
et al., 2008; Yang and Seed, 2003). The large size (150 kb) of BACs
though precludes the use of conventional restriction enzyme
manipulations to insert an intact HIV provirus. Recent studies have
utilized new techniques based on recombination using λ phage
proteins (recombineering) (Lee et al., 2001; Muyrers et al., 1999;
Sawitzke et al., 2007; Sharan et al., 2009; Zhang et al., 1998). We have
utilized a combination of recombineering and recombination using
the P1 phage encoded enzyme Cre, to develop a strategy for the
reinsertion of a complete HIV-1 provirus into deﬁned sites within
BACs (Lee and Saito, 1998; Sorrell and Kolb, 2005). To test this system,
we have inserted complete HIV-1 proviral genomes into three
previously deﬁned integration sites found in resting, latently infected
CD4 T cells (Han et al., 2004; Ikeda et al., 2007). The results of our
studies demonstrate differences in capacity of different integration
sites to spontaneously produce infectious virus and to be reactivated
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Fig. 1. BAC clones containing integration sites identiﬁed in latent T cells. Three BAC
clones were used that contain integration sites that have previously been identiﬁed in
latent T cells. Panel A. The BAC clone containing the complete gene for Top2A (Jacobson
et al., 2004). The complete gene for Top2A (RP11-5809) (29,375 bp) and surrounding
genes is shown. The location of the inserted HIV proviral genome is shown. Panel B. The
BAC clone containing the genomic regions for DNMT1 (RP11-152C7). The complete
gene for DNMT1 (61,790 bp) along with surrounding genes is depicted (arrows denote
start/stop transcription). The approximate location of the inserted provirus is indicated.
Panel C. The BAC clone (RP11-597J7) containing a region of the BACH2 gene (370 kb).
The BAC clone encompasses the 4th, 5th, and 6th introns. The location of the inserted
HIV provirus in the 5th intron is shown.
152 P.G. Eipers et al. / Virology 410 (2011) 151–160that highlight the importance of the host gene and surrounding
chromatin in controlling HIV-1 gene expression and latency.
Results
Selection of integration sites
Previous studies have identiﬁed integration sites in latently
infected T cells that were obtained from patients who had responded
to highly active anti-retroviral therapy (HAART). In one study, 75
integration sites were identiﬁed while a second study reported on
over 400 sites (Han et al., 2004; Ikeda et al., 2007). A drawback of all of
these studies, though, was that it was not possible to determine if full-
length HIV-1 proviruses were present at these sites, due to the PCR
technique used to identify the integration sites. To understand the
signiﬁcance of the identiﬁed integration sites in latency with respect
to how host gene expression and chromosome dynamics impact HIV
latency, it is important to determine whether or not full-length HIV-1
proviruses when positioned back at the integration site can be
expressed and be reactivated from latency (Jordan et al., 2001;
Lewinski et al., 2005; Quivy et al., 2007).
To address this issue, we have utilized technology that is based on
bacterial artiﬁcial chromosomes (BACs). BACs can incorporate up to
300 kb of DNA, although most BACs that are available contain only
150 kb of DNA. Due to their large size, it is not possible to use
conventional molecular biology techniques to manipulate these
plasmids. In recent years, several techniques have been developed
to allow the successful manipulation of BACs (Han et al., 2004; Ikeda
et al., 2007; Lee et al., 2001; Muyrers et al., 1999; Sawitzke et al., 2007;
Sharan et al., 2009; Zhang et al., 1998). In the current study, we have
targeted three previously identiﬁed integration sites (Han et al., 2004;
Ikeda et al., 2007). One of these sites is within an intron of the gene for
DNA topoisomerase II (Top2A), second is within an intron of the gene
for DNA methyltransferase (DNMT1), while third is within an intron
of the basic leucine transcription factor 2 (BACH2) gene. All three are
on different chromosomes and contained within different BACs
(Fig. 1). The genes, exons, introns, and ﬂanking regions of Top2A
and DNMT1 are completely contained within a BAC. Based on
previous studies, we anticipate that these BAC clones will contain
the necessary host cell genomic information to accurately reﬂect the
chromosome environment (Schubeler et al., 1998; Testa et al., 2003;
Yang and Seed, 2003). The BAC clones were chosen to position the
target site in the center of the BAC so that the complete gene (Top2A
or DNMT1) as well as surrounding genes would be included. A third
target site was chosen in the intron of the BACH2 gene, since a
previous study had identiﬁed introns of BACH2 as a preferred site for
HIV-1 integration in latently infected T cells (Ikeda et al., 2007). In
contrast to the other two target sites, the gene for BACH2 is too large
for a single BAC and does not contain the cellular promoter.
Construction and characterization of BAC-HIV
The procedure for the insertion of a full-length HIV proviral
genome into a deﬁned site in a BAC clone is depicted in Fig. 2. The
procedure ﬁrst required targeting the RPSL-LoxP gene to a speciﬁc site
in the BAC using recombineering. As a result of the construction, 20 bp
was added 5′ and 3′ to the target site. The RPSL gene was ﬂanked by
two unique LoxP sites. Characterization of the insertion site was
accomplished by using PCR primers 500 bp 5′ and 3′ (in the BAC
sequence) along with internal primers in the RPSL gene (Table 1).
DNA sequence analysis revealed the correct 5′ and 3′ insertion (data
not shown). To substitute the HIV-1 provirus for the RPSL sequence,
we made use of the LoxP sites and transient expression of the Cre
recombinase in Escherichia coli. The design of the HIV provirus with
ﬂanking LoxP sites in a plasmid that only replicated in E. coli (pir+)
cells is described in the Materials andmethods section. The advantageof this system is that we could transform supercoiled HIV-LP plasmid
into the BAC–RPSL E. coli rather than linear DNA, which was too large
to obtain reproducibly efﬁcient transformation. The presence of the
RK6γ origin ensured that the plasmid encoding HIV-LP would not
replicate in the E. coli, potentially confounding our results. Successful
exchange of the HIV-LP for the RPSL was monitored by the loss of the
resistance to kanamycin as determined from replicate plating.
Oncewe identiﬁed candidate BAC-HIV by sensitivity to kanamycin,
we used PCR to characterize the target site and position of HIV-1
within the BAC clone. The use of PCR primer speciﬁc for the predicted
ﬂanking sequencewithin HIV-1 allowed the conformation of targeting
at the speciﬁc site at the 5′ and 3′ positions of the HIV-1 proviral
genome. DNA sequencing of PCR products conﬁrmed that the HIV-1
proviral genome was positioned at the integration site. As a
consequence of the procedure, an additional 20 nucleotides in
addition to the 34 bp LoxP site was also positioned 5′ and 3′ of the
HIV-1 proviral genome. Since the proviral genome was positioned
within introns of the target genes, it is unlikely that this additional
54 bp 5′ and 3′ of the HIV genome would impact the subsequent host
or viral gene expression.
To further characterize the BAC-HIV clones, we performed a
“ﬁngerprint” analysis comparing a restriction digest of the original
BAC clone with the constructed BAC-HIV (Fig. 3). As would be
expected for such a large plasmid, the restriction digest generated a
complex pattern, depending upon the number of restriction sites
present within a BAC clone. Most importantly, the EcoRI restriction
digest of the original BAC clone with the BAC-HIV revealed that the
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Fig. 2. Construction of BAC–HIV. The steps to insert an intact HIV-1 provirus into a
speciﬁed site in a BAC. See text for details.
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of the original BAC had occurred during the insertion of the HIV-1
provirus. To conﬁrm that there was a single insertion site within the
BAC clone, we performed a Southern blot using a restriction enzyme
that cuts at a single site within the HIV-1 genome (SphI). Using a
probe speciﬁc for HIV-1, we would expect that a single band would be
obtained if only a single insertion site had occurred within the BAC. As
the results in Fig. 3 clearly show, a single insertion was obtained for all
of the BAC-HIV used in this study.
Virus production from transfected BAC
We next tested the potential of the BAC-HIV for production of HIV-1
following transfection into 293 T cells. For the three sites analyzed,
HIV-1 proviruses were positioned within introns of the Top2A, DNMT1,
or BACH2 genomic constructs; two of these genomes (Top2A and
DNMT1) have complex splicing patterns with multiple introns and
exons, while the third BAC-HIV is positionedwithin the 5th intron of the
BACH2 gene that does not contain the host transcription promoter
(Fig. 4).
A previous study reported on transfection of BACs using FuGENE as
the facilitator (Strehlow et al., 2007). Since the HIV-1 encodes a GFP as
a fusion with Nef, we could easily monitor the transfection by the
presence of GFP positive 293 T cells. In the case of HIV positioned at
introns of DNMT1 (BAC–HIV–DNMT1) or BACH2 (BAC–HIV–BACH2),
we found an increasing amount of GFP-positive cells with increasing
concentrations of DNA reaching a plateau that was approximately
0.4% that for HIV-LP. The transfection of BAC–HIV–Top2A gave
approximately 0.1% that of GFP expressing cells as that for HIV-LP
(data not shown).Since the GFP gene was positioned as a fusion with the Nef mRNA,
it was possible that expression of GFP would not necessarily correlate
with the production of infectious virus. As our goal was to develop a
system to study the production of infectious virus from HIV-1
proviruses positioned with BACs, we analyzed the supernatants
from the transfected 293 T cells for production of infectious virus
using a JC53-BL assay (Fig. 5). Analysis of the supernatants from HIV-
LP-transfected 293 T cells at the optimum DNA amount revealed the
presence of infectious virus at approximately 103 infectious units per
milliliter of tissue culture supernatant, an amount consistent with that
found for transfection of HIV-1 proviruses that do not have the gene
for GFP as a fusion with Nef (Moore-Rigdon et al., 2005). Analysis of
the supernatants from cells transfected with BAC–HIV–DNMT1 or
BAC–HIV–BACH2 revealed production of infectious virus with titers
approximately 2% that of HIV-LP. In contrast, the amount of virus
produced from transfection of BAC–HIV–Top2A was approximately
fourfold less than seen for BAC–HIV–DNMT1 and BAC–HIV–BACH2.
Although complete gene silencing was not observed from any of the
BAC–HIV plasmids following transfection, there were consistent
differences with respect to the amounts of HIV-1 produced from
each BAC–HIV following transfection (Fig. 5).
Selection of transfected cells using GFP expression
Since we analyzed the HIV-1 gene expression from transfected
BACs at early times post transfection, it was unlikely that the BACs had
integrated into the host chromosome. To examine the GFP and HIV-1
gene expression in cells where the BAC integrated into the
chromosome, we co-transfected BAC–HIV or BAC–RPSL with pIRES-
puro at ratios where pIRES-puro was limiting. The transfected 293 T
cells were selected with puromycin and resistant colonies from the
lowest dilution of pIRES-puro were isolated to increase our chances to
obtain cell lines with the BAC–HIV. We ﬁrst screened the cell colonies
by PCR for presence of the HIV genome using primers speciﬁc for the
PBS, Gag and Nef. Positive colonies were identiﬁed for BAC–HIV–
Top2A, BAC–HIV–DNMT1, or BAC–HIV–BACH2. We obtained the
greatest number of colonies containing BAC–RPSL compared to the
corresponding BAC–HIV. The BAC–HIV–Top2A, from two independent
transfections, gave a greater colony number than BAC–HIV–DNMT1 or
BAC–HIV–BACH2.
Several colonies from each BAC–HIV were chosen for further
characterization. Most of the BAC–HIV colonies had single HIV-1
genomes as estimated by qPCR (Table 2). Two colonies from the BAC–
HIV–Top2A had ﬁve HIV genome copies, while 1–3 genomes were
found in the other BAC–HIV–Top2A clones. The BAC–HIV–DNMT1 and
BAC–HIV–BACH2 cell clones had one HIV genome per cell as
determined by qPCR. All of the BAC–HIV cell clones contained at
least 500 bp 5′ and 3′ of the insertion site as determined using PCR
with primers spanning the host cellular DNA and the 5′ or 3′ end of
the HIV genome. Using PCR we conﬁrmed the presence of host DNA
between the cellular promoter and the inserted HIV genome (8–12 kb
for DNMT1 and Top2A, respectively) (data not shown).
We next analyzed the colonies for HIV-1 gene expression
(Table 2). By microscopic inspection under UV illumination, we
observed only a few GFP-positive cells. We conﬁrmed the low
expression using FACs resulting in less than 2% GFP-positive from
all BAC–HIV clones. We also analyzed the supernatants for
infectious HIV-1 as determined by the JC53-BL assay. With one
exception, none of the colonies spontaneously produced HIV-1. The
exception, BAC–HIV–DNMT1 (3), had 100–200 IU/ml of infectious
HIV-1 per milliliter.
We next determined if HIV-1 expression in the cell clones could be
reactivated by stimulation with TNF-α (Schreck et al., 1991). By visual
inspection of the cell cultures under UV ﬂuorescence, we noted a clear
increase in GFP-positive cells following TNF-α stimulation in some of
the BAC–HIV clones. All of the BAC–HIV–Top2A colonies had GFP
Table 1
Oligonucleotide primers used to construct BAC–HIV.
A. Construction of LoxP-RPSL
1. LoxP5171: TCGCGGAATTCCGATAACTTCTATAATGTGTACTATACGAAGTTATGGCCTGGTG ATGATGGCGGGATCGTTG
2. LoxP2272: GTAGGGAAGCTTCCATAACTTCGTATAGGATACTTTATACGAAGTTATTCAGAAG AACTCGTCAAGAAGGCGATAGAAGGCG
B. Construction of LoxP-RPSL targeting cassettes with 60 bp homology regions to designated genes
1. Top2A
5′ Inner: CCACACCCAACTAATTTTTGTATTTTTAGTGGAGACAGGGTTTGGTTTCT CGCATATTGGCT
3′ Inner: TTTGGGAGGCCGAGGCAGGCGGATCGCCTGAGGTCAGGCGGGCTAGTG CGTAGTCGTTGG
5′ Outer: CCTGCCTCAGCCTCCCGAGTAGCTGGGATTGCAGGCGGATGCCACCACA CCCAACTAATTTTTGTA
3′ Outer: TTAGGCTGGGCGTGGTAGCTAACATCTGTAATCCCAGAACTTTGGGAGG CCGAAGGCAGGC
2. DNMT1
5′ Inner: CTTCCTCCCAGGCTCAAAGATTTGGAAAGAGACAGCTTAAGGTGTTCTC GCATATTGGCT
3′ Inner: AGCCACAAAGTGTGTCAGTCAGATTTGGTAATAAGAAAAAGGCTAGTGC GTAGTCGTTGG
5′ Outer: TGAAGTTGCTTAACAAGTGTTTGTATTTTCTCCCCTATTTCTTCCTCCCAG GCTCAAAGA
3′ Outer: GAAAAAATGCAAAATCCATTTAAAGAAAACAAATTTCTTTTTATGAGCC ACAAAGTGTGTCAGTCA
3. BACH2
5′ Inner: GTAATATCCTGCTGAAATGTTTAGGGGAAAGTGTGCTGATTGGTGTTCTC GCATATTGGCT
3′ Inner: GCTTATTTCATTACACATCCATCCATCTATATCCATCAGAGGCTAGTGCG TAGTCGTTGG
5′ Outer: GCCTCAAAAGAAAAAAACTATAAACTAATCTTAAACTCTAGCAAGTAAT ATCCTGCTGAAATGTTT
3′ Outer: TGTATCCCATCACTTAGATTCCACGATTAACATTTTATTATGCTTATTTCA TTACACATCC
C. Construction of HIV-LP
RK6 origin/kanamycin recombineering (5′ LTR-LoxP) to generate 60 bp homology regions
5′ Inner: GCAGCACTGCACTCCAGCCTGGCGGCCGCAACCATCATCGATGAATTGC
3′ Inner: CTTTTTTGGGACCAAATTAGCCCTTCCAATAACTTCGTATAGTACACATT ATACGAAGTTATGTCAGCGTAATGCTCTGCCA
5′ Outer: CGGTGCGGCCTCTTCGCTATTACGCCAGGGGAGGCAGAGATTGCAGTAA GCTGAGATCGCAGCACTGCACTCCAGCC
3′ Outer: GGGAAGTAGCCTTGTGTGTGGTAGATCCACAGATCAAGGATCTCTTGTC TTTTTTGGGACCAAATTAGC
Chloraphenicol recombineering (3′-LTR-LoxP) to generate 60 bp homology regions
5′ Inner: TCAGTGTGGAAAATCTCTAGCATAACTTCGTATAAAGTATCCTATACGA AGTTATTGATAAGATCACTACCGGGCG
3′ Inner: TGAGCCCTCACCCTGTGGTCTGGCGGCCGCCTTGAGGGGGCCCCACGCG TTTACGCCCCGCCC
5′ Outer: GTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACC CTTTTAGTCAGTGTGGAAAATCTCTAGC
3′ Outer: GGGTGTTTATGTCTTGGGTGTTTATGTCTTGGGGACTGAGCCCTCACCCT GTGGTCTG
D. Southern analysis of HIV-LP in BAC
Biotinylated oligomer: [BioTEG]CGGAATTCTCTCCTTCTAGCCTCCGCTAGT
E. Characterization of BAC–HIV in chromosome
Primer binding site
5′
5′-CCTTGAGCATGCGATCTACCACACACAAGGC
3′
5′-CGGAATTCTCTCCTTCTAGCCTCCGCTAGT
Gag
5′
5′-GCAGGGAGCTAGAACGATTCG
3′
5′-CAGCCAAAACTCTTGCCTTATG
Nef
5′
5′-CCAGTCACACCTCAGGTCCC
3′
5′-CTAACACTTCTCTCTCCGGG
F. Oligonucleotides used for ampliﬁcation of 500 bp 5′ and 3′ surrounding HIV integration site
Top2A
5′-GGGAAGATAATGATTATGACAGATCAGGTC
3′-GTTCTATATGGGTTTCATTACAAACCTTTG
DNMT1
5′-ATAATTGTGTTACAGAGCTGCTATGTAATC
3′-TTACAATCCAGAGTAGATTGTTTAGGAACT
BACH2
5′-TAACAGCCGCAGGGTGTGGTATGTGTCTTC
3′-GAGTCACAAAAATAATTCTAAAACAGGGCA
G. Oligonucleotides used for ampliﬁcation of promoter region for Top2A and DNMT1
Top2A
CCTGGAGAATAAAACATCCTTTGCTTTTCTCCTGCACATT
DNMT1
CCTCTCCGGTTCAAGTGATCTTCCTGCCTCAACCTCTCGA
Footnotes: DNA oligonucleotides purchased from Operon-Euroﬁns.
154 P.G. Eipers et al. / Virology 410 (2011) 151–160expression ranging from 25% to 40%. Two of the BAC–HIV–DNMT1 had
GFP expression ranging from20% to 40%,while a third had very lowGFP
expression of 3%, although this value was greater than the non-
stimulated valueof 0.5%.Wedidnotea greaternumber of intenselyGFP-positive cells from the BAC–HIV-DNMT clones as compared to the BAC–
HIV–Top2A (conﬁrmed by FACs (data not shown)). Interestingly, both
of the BAC–HIV–BACH2 cell clones showed lowGFP expression thatwas
unchanged from the non-stimulated cultures (Table 2).
Fig. 3. Fingerprinting and Southern blot analysis of BAC–HIV. The BAC clone and BAC–
HIV were isolated and digested with EcoRI, which restricts the BAC multiple times but
the HIV-proviral DNA only once followed by electrophoresis on 0.8% agarose gel. The
DNA was visualized by ethidium bromide staining. The panels are as marked for BAC
(Lane 1) and BAC–HIV (Lane 2). In a second reaction, the BAC–HIV was digested with
SphI, which restricts the BAC multiple times and the HIV-1 provirus once (panel D). The
DNA fragments were electrophoresed on a 0.8% agarose gel and transferred to nylon
membrane and probed with a biotinylated primer speciﬁc for HIV (Table 1). The blot
was developed using streptavidin–alkaline phosphatase.
155P.G. Eipers et al. / Virology 410 (2011) 151–160To test for infectious HIV-1, we analyzed the supernatants from the
TNF-α-stimulated cultures using the JC53-BL assay. The two BAC–
HIV–BACH2 colonies, which did not show any GFP expression after
TNF-α stimulation, did not release any infectious virus in the
supernatant. The BAC–HIV–Top2A colonies with the greater genomeHIV
HIV:BACH2
A
B
C
HIV
HIV:DNMT1
HIV
HIV:Top2A
Fig. 4. Intron–exon map of target genes. The location of introns–exons and position of
the inserted HIV provirus are depicted. The vertical bars above the lines indicate exons
with the introns shown linking the arrows below the bar. The genes are presented in 5′
to 3′ at the start site (arrow), with the HIV-1 provirus positioned in introns in a 5′ to 3′
direction. Panel A. The gene for Top2A (29,375 bp). The HIV provirus is positioned in
the 13th intron. Panel B. The gene for DNMT1 (61,790 bp). The HIV provirus is
positioned in the second intron. Panel C. The complete gene for BACH2 (370,500 bp) is
shown with the HIV provirus positioned in the 5th intron. Note that the BAC clone
contained the 4th and 5th introns without the promoter is boxed.copy numbers (5) gave the highest amount of infectious HIV-1 (up to
1000 IU/ml), while the colonies with three and two genomes gave
only 70–100 IU/ml. The BAC–HIV–Top2A (5)with a single genome did
not produce infectious virus, even though the percentage of GFP-
positive cells increased from 1% to 30%. In contrast, the amount of
infectious virus from the BAC–DNMT1 colonies (all which had single
genomes)was considerably greater than that for the BAC–HIV–Top2A.
Indeed, even the BAC–HIV–DNMT1 (2) colony with a low GFP
expression following TNF-α stimulation (3%) gave approximately
ﬁvefold more infectious virus than the BAC–HIV–Top2A with 2 and 3
HIV genomes. We also noted that the reactivation of the BAC–HIV–
DNMT1 produced a greater number of brighter GFP-positive cells (as
determined by FACs), indicating that the HIV-1 genome positioned at
the DNMT1 might be more efﬁciently reactivated following TNF-α
stimulation. Further support for the DNMT1 site being conducive to
reactivation comes from the ﬁnding that BAC–HIV-DNMT (3) cell line
that produced a low level of endogenous virus produced the greatest
amount of infectious virus following TNF-α stimulation. Collectively,
the results of these studies show clear differences between each BAC–
HIV positioned at different integration sites with respect to the
capacity to spontaneously produce infectious HIV-1 and reactivate
from latency.
Discussion
In the current study, we have described a system to insert
complete HIV-1 proviruses into BACs at three previously identiﬁed
integration sites found in latently infected T cells. Transfection of the
BAC clones with the inserted HIV-1 proviruses into 293 T cells
resulted in production of different amounts of infectious HIV-1. Cell
lines were established for each BAC–HIV and revealed differences
between the different integration sites with respect to virus
production and capacity for reactivation.
Previous studies have identiﬁed integration sites of HIV-1
proviruses from in vitro infection of cells (Brady et al., 2009; Bushman
et al., 2005; Lewinski et al., 2005; Schroder et al., 2002; Vatakis et al.,
2009; Wang et al., 2007). From an analysis of an extensive number of
integration sites, HIV-1 was found to integrate, for the most part, into
introns of actively transcribed genes (Lewinski et al., 2005; Wang
et al., 2007). There have been fewer studies to identify the integration
sites from patients that have controlled HIV-1 viremia using HAART
(Han et al., 2004; Ikeda et al., 2007). Consistent with the in vitro
studies, HIV-1 was found predominately in introns of cellular genes.
Analysis of sequential samples from patients on HAART revealed that
several genes were repeatedly identiﬁed and several clusters of
integration sites were identiﬁed (Han et al., 2004; Ikeda et al., 2007).
The signiﬁcance of these repeat and cluster integration sites was not1
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Fig. 5. Infectious HIV produced following transfection in 293 T cells. Equal amounts of
the designated DNA were transfected into 293 T cells using FuGENE. After 72 h, the
amount of infectious virus in the supernatant was analyzed by the JC53-BL assay. The
data are presented in infectious units (i.e., β-galactosidase-positive cells) per milliliter.
The data presented are from one transfection that is representative of three
independent experiments.
Table 2
Analysis of BAC–HIV 293 T cell clones.
BAC–HIV Copy
numbera
%GFPb IU/mlc +TNF-αd
% GFP IU/ml
BAC–Top2A (1)e 5 0.7 0 25 800–1000
BAC–Top2A (2) 5 0.4 0 55 800–1000
BAC–Top2A (3) 3 1 0 40 70–100
BAC–Top2A (4) 2 1 0 55 70–100
BAC–Top2A (5) 1 1 0 32 0
BAC–DNMT1 (1) 1 1 0 21 400–500
BAC- DNMT1 (2) 1 0.6 0 3 400–500
BAC- DNMT1 (3) 1 2 100–200 35 8000–9000
BAC–BACH2 (1) 1 0.3 0 4 0
BAC–BACH2 (2) 1 0.1 0 0.3 0
a Copy number determined by qPCR using HIV-LP plasmid as standard. PCR primers
speciﬁc for gag used for assay.
b Percent GFP following FACs. Values presented for single analysis but representation
of these independent assays with variation less than 10%.
c IU/ml determined by JC53-BL assay. Values represent range from 3 independent
assays in which β-galactosidase-positive wells. Zero values indicate no blue cells visible
in at least 2 wells.
d Cultures were incubated with TNF-α (10 ng/ml) for 72 h prior to analysis by FACs
or assay of supernatants for infectious HIV.
e The corresponding BAC–RPSL colonies for each BAC–HIV were negative for HIV
genome copies, GFP and HIV.
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integration sites is that it was not possible to determine if biologically
active proviruses were present at these sites. Given the fact that the
majority of HIV-1 infections result in the production of defective
viruses that have undergone incomplete reverse transcription, it is not
clear that these sites would even support production of HIV-1 gene
expression from intact proviruses (Han et al., 2007; Mok et al., 2007).
Thus, if one were to understand the elements of reactivation of HIV
from latency, it would be imperative to have the system in which full-
length HIV proviruses could be studied in the context of host cell
chromatin that would impact viral gene expression.
One way to approach this problemwould be to reinsert intact HIV-
1 proviruses into previously identiﬁed integration sites within the
host cell chromosome. One such strategy has been developed using
lenti-virus vectors containing sites for recombinases (e.g., the FLP
recombinase) to insert sites within the chromosome of cell lines
(Schubeler et al., 1998). The addition of a target DNA sequence,
ﬂanked by FLP sites, in the presence of the FLP recombinase can be
used to recombine DNA into chromosomes. Following the appropriate
selection, cell lines can be obtained with the appropriate gene target.
However, this process relies on the integration of lentivirus vectors to
select for integration sites and does not allow selection or analysis of
previously identiﬁed sites. If one wants to use a selected site, the use
of larger plasmids with sufﬁcient ﬂanking DNA sequence is required
for targeted integration (Testa et al., 2003; Yang and Seed, 2003). In
most cases, BACs are the vector of choice because of their capacity to
carry large regions of the human chromosome (up to 300 kb),
although 150 kb is more typical. Recently, new technologies have
emerged that utilize homologous recombination using λ phage genes
that allow insertion of foreign DNA at speciﬁc sites within BACs
(recombineering) (Sharan et al., 2009). In the current study,
recombineering has been used along with the P1 recombinase Cre
to insert HIV-1 proviruses into previously deﬁned integration sites
within BACs. Because of their size, the BACs contain most if not all of
the chromosomal elements that control gene expression, thus
providing a unique system in which to study the regulation of HIV
gene expression and the impact of host gene expression. Furthermore,
in contrast to the process of making cell lines, the manipulations of
BACs using recombineering/Cre recombinase allow the analyses of
multiple, independent integration sites and are only limited by the
number of BACs that contain these sites.In the current study, we have focused on three previously
identiﬁed HIV-1 integration sites. Two of these were found in genes
identiﬁed in latent T cells corresponding to the gene for DNA
methyltransferase1 (DNMT1) and for topoisomerase II (Top2A)
(Han et al., 2004). The corresponding BAC containing these genes
consisted of the entire genomic region for DNMT1 and Top2A and
surrounding genomic DNA contained within 150 kb. A third target
gene, BACH2, was shown in previous studies to be a potential
preferred site for HIV integration because it had been isolated
sequentially in patients who had low viral loads as a result of
HAART therapy (Ikeda et al., 2007). Since the gene for BACH2 is larger
than that which can be contained within a single BAC, the construct
made for this study did not contain the cellular promoter for BACH2
and the HIV-1 provirus was positioned within the ﬁfth intron of the
BACH2 gene, previously shown to be a site of multiple insertions in
latent T cells (Ikeda et al., 2007). Transfection of the BAC–HIV clones
into 293 T cells resulted in HIV-1 gene expression determined by GFP
ﬂuorescence (as a result of GFP–Nef fusion mRNA) and virus
production as determined by the analysis of supernatants of
transfected cells. Two of the BAC–HIV, BAC–HIV–DNMT1 and BAC–
HIV–BACH2, produced similar levels of HIV-1 following transfection,
while the third, BAC–HIV–Top2A, consistently produced approxi-
mately fourfold less virus.
Since all three BAC–HIVs were similar in size, we believe that the
difference in virus expression is likely due to the transcriptional
activity of the host gene or the chromosomal regulation that occurred
up or downstream of the inserted HIV-1 provirus (Jones and Peterlin,
1994; Jordan et al., 2001, 2003; Quivy et al., 2007). To further explore
the regulation of virus expression, we generated cell lines following
transfection with the BAC–HIV. Many times BACs are sufﬁciently large
to contain key regulatory elements required for host gene expression
(Giraldo and Montoliu, 2001). This is an important issue because the
frequency of homologous recombination is low, although a previous
study suggested that for BACs, the percentage is increased (Yang and
Seed, 2003). With respect to the BAC–HIV in this study, we have
chosen BACs with the target cellular gene positioned near the middle
of the BAC to optimize potential for cellular regulation. Based on PCR
analysis for BAC gene sequences as described by Yang and Seed, most
probably the BAC–HIV has not undergone homologous recombination
(Eipers and Morrow, unpublished) (Yang and Seed, 2003). However,
analysis by PCR has found that the cellular promoter region is intact,
so the expression of HIV-1 is most probably still inﬂuenced by the
surrounding cellular DNA. Cell lines were obtained from transfection
of all BAC–HIV, but the greater numbers were obtained from BAC–
HIV–Top2A compared to the other BAC–HIV. Coincidentally, the BAC–
HIV–Top2A gave the lowest amount of virus following transfection.
One explanation of these results is that the expression of HIV gene
products (e.g., Vpr) following transfection is deleterious to 293 T cells
(Chang et al., 2000; Han et al., 2008; Jones and Peterlin, 1994; Jordan
et al., 2001, 2003; Lenasi et al., 2008; Quivy et al., 2007; Stewart et al.,
1999). If the provirus gene expression cannot be reduced or silenced,
the cell would probably die during the selection process (Chang et al.,
2000; Stewart et al., 1999). Additional support for the toxicity of the
HIV-1 gene products comes from the fact that we readily isolated cell
clones containing HIV-free BAC–RPSL from all three integration sites
that were analyzed.
The development of cell lines allowed us to more directly assess
the potential for latency and reactivation between the different
BAC–HIV. Insights into the complexities of HIV-1 latency emerge
from the comparison of the BAC–HIV–Top2A and BAC–HIV–DNMT1,
where both BACs contain the complete host gene and surrounding
DNA. Cell lines containing these BAC–HIVs all demonstrated latent
HIV-1 production that was reactivated with a known inducer of the
HIV-LTR, TNF-α (Schreck et al., 1991). Thus, for the ﬁrst time, we
have veriﬁed that HIV-1 genomes positioned at integration sites
identiﬁed from T cell isolated in vivo can be a host for latent viral
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found that BAC–HIV–DNMT1 (3) spontaneously produced low but
clearly detectable amounts of virus that was substantially increased
following stimulation with TNF-α. In contrast, no virus was seen in
cultures from BAC–HIV–Top2A (5) with a single genome, even with
TNF-α stimulation. However, clones with increasing genome
numbers of BAC–HIV–Top2A did produce virus after stimulation
with TNF-α, which is consistent with results from transfection,
where multiple copies of the BAC–HIV–Top2A could have been
present in the transfected cell. Thus, the regulation of proviral
latency and capacity for reactivation differ for HIV-1 in the Top2A or
DNMT1 integration sites. Most probably, this is due to differences in
the transcription of the host gene, which could impact HIV
expression by transcriptional interference (Han et al., 2008; Jones
and Peterlin, 1994; Jordan et al., 2001, 2003; Lenasi et al., 2008;
Quivy et al., 2007). Interestingly, previous studies have found that
transcription of Top2A is cell cycle-dependent, while expression of
DNMT1 occurs throughout the cell cycle (Falck et al., 1999; Szyf et
al., 1991). Indeed, Top2A transcription was not detected in resting T
cells but was induced upon activation, while DNMT1 was tran-
scribed in both resting and activated T cells (Han et al., 2008).
Studies are underway to manipulate the host promoters (Top2A and
DNMT1) and re-position the HIV provirus at different distances from
the promoters to further address the issue of how the host gene
transcription impacts the establishment and maintenance of
latency.
Both cell clones from the BAC–HIV–BACH2 did not produce virus,
even when stimulated with TNF-α. We interpret this result as
indicating that those HIV-1 genomes were silenced following
integration of BAC–HIV–BACH2 into the chromosome. Given that
the BAC–BACH2 did not contain the cellular promoter, it was
possible that the HIV genome in this conﬁguration was now more
easily silenced because the cellular promoter was not present to
help maintain the characterized genome in an open state. Interest-
ingly, we chose BACH2 for analysis because of a previous report that
this gene was a target for multiple and recurrent HIV-1 insertions in
resting T cells of patients on HAART (Ikeda et al., 2007). However,
HIV-1 was not produced in vitro following activation of PBMC from a
patient with the multiple BACH2 insertions (Ikeda et al., 2007). A
reason for the observed recurrent isolation of HIV-1 integration in
the BACH2 gene might be due to a more efﬁcient silencing at this site
following integration. Alternatively, it is possible the insertion of the
HIV-1 genome could impact the host cell promoter, which might
provide a selective advantage to the cell (Bokhoven et al., 2009).
Further studies can now be done using this system to compare the
effect of full-length HIV proviruses and defective genomes contain-
ing HIV LTR on host cell gene expression to gain insights into the
dynamic interplay between host and viral gene expression, which
will be needed to understand and eventually develop safe methods
to manipulate latency.Materials and methods
Plasmids
The BACs were obtained from the Children's Hospital Oakland
Research Institute (CHORI). Theplasmids containingRPSLgeneencoding
antibiotic resistance to kanamycin and streptomycin, pSC101-BAD-gba,
and pCre were obtained from Gene Bridges Ltd. (Dresden, Germany).
The pMOD4, Kan-RK6γ ori genes and E. coli (pir+) were obtained from
EpiCentre. The plasmid encoding HIV-1 (pNLENGires) with gfp posi-
tioned prior to nef has been previously described (Levy et al., 2004). The
antibiotics were obtained from Sigma and used at the following ﬁnal
concentrations: chloramphenicol 15 μg/ml, kanamycin 15 μg/ml, tetra-
cycline 5 μg/ml, and ampicillin 100 μg/ml.Construction of RPSL gene with LoxP sites and insertion into BAC
The RPSL gene was modiﬁed to include two 34-nucleotide
sequences at the 5′ and 3′ end that are recognized by the P1 phage
enzyme, Cre; these sites designated as LoxP(5171) and LoxP(2272)
have been modiﬁed from the wild-type LoxP sites such that they will
only recombine with the homologous LoxP sites (Lee and Saito, 1998;
Sorrell and Kolb, 2005). The DNA oligonucleotides were designed to
include ﬂanking EcoRI and HindIII sites (Table 1). PCR was used to
amplify the RPSL gene with LoxP(5171) and LoxP(2272) at the 5′ and
3′ ends, respectively.
The PCR product was puriﬁed using the Qiagen puriﬁcation kit. The
ampliﬁed DNA fragment (approximately 1.3 kb) was digested with
EcoRI and HindIII, then cloned into pMOD4, also digested with EcoRI
and HindIII, which contains the RK6γ ori so it will only grow in cells
that supply replication proteins (pir), not found in commonly used E.
coli strains (Gong et al., 2002). The RPSL transformed E. coli (pir+)
were selected on plates containing kanamycin. Recombinants were
characterized by restriction digest and DNA sequencing to ensure the
intact LoxP(5171) and LoxP(2272) sites were present; the plasmid
was named RPSL-LoxP.
To position the RPSL-LoxP at speciﬁc sites in BACs, we have used
the recombineering procedure that relies on λ recombination
proteins. The ﬁrst step was to use PCR with two nested 5′ and two
3′ 60 nucleotide overlapping oligonucleotides to amplify the RPSL-
LoxP gene. The ﬁrst PCR (inner) uses 20 of the 60 nucleotides speciﬁc
for the 5′ and 3′ ends of the RPSL-LoxP gene. A second PCR (outer) is
then used with 60 nucleotide DNA oligomers in which 20 bp are
complementary to the 5′ and 3′ ends of the inner PCR product
(Table 1). The ﬁnal PCR product then has 60 bp at the 5′ and 3′ ends
that are complementary to the target site in the BAC. The use of the
RK6γ system reduces the possibility of generating E. coli that contain
both the BAC plasmid and carry over contamination from the pMOD4-
RPSL-LoxP PCR template (that could also confer kanamycin resis-
tance). For recombineering, the E. coli containing the target BAC are
transformed with the plasmid pSC101-BAD-gba by electroporation
and transformants are selected using tetracycline at 30 °C (due to the
temperature sensitive origin of replication in pSC101-BAD-gba).
Transformants were characterized for the presence of pSC101-BAD-
gba by restriction digest with EcoRI. The expression of the λ
recombination proteins are under control of the arabinose operon.
To induce the production of the λ proteins, the E. coli containing the
BAC and pSC101-gba were grown at 30 °C with chloramphenicol/
tetracycline to an OD600 of 0.6. Arabinose was then added to a ﬁnal
concentration of 0.5%, and the cells were incubated at 37 °C for 1 h
with vigorous shaking. Following the incubation, the cells were then
processed for electroporation. The induced E. coli containing the target
BAC and pSC101-BAD-gba were electroporated with the PCR
ampliﬁed RPSL-LoxP containing 60 nucleotides of 5′ and 3′ comple-
mentarity with the BAC target site using standard conditions (25 μF,
1.2 kV, 200 Ω). Following electroporation, the cells were allowed to
recover for 1 h at 37 °C allowing the λ-mediated recombination and
then incubated on plates containing chloramphenicol (to select for
BAC) and kanamycin (to select for RPSL) at 35 °C (which selected
against pSC101-BAD-gba). Colonies that grew were screened for the
presence of the RPSL gene in the correct position by PCR using
oligonucleotides complementary to positions 500 nucleotides 5′ and
3′ to the target site in the BAC. Those colonies that gave correct PCR
product size were used for further construction of BAC–HIV.
Construction of BAC with HIV proviruses positioned speciﬁc integration
sites
Based on preliminary studies, it was not possible to use
recombineering to insert a complete HIV-1 provirus into speciﬁc
sites of the BAC plasmid due to the 10 kb size of the HIV-1 proviral
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necessary 80 bp of homology required for recombineering; in
addition, transformation of E. coli with linear 10 kb DNA was too
inefﬁcient for recombineering. To circumvent these issues, we utilized
the Cre-LoxP system to recombine an intact HIV-1 proviral genome
with the RPSL fragment ﬂanked by LoxP sites. A previous study
demonstrated that slight modiﬁcation of the LoxP sequence (mutants
5171 and 2272) results in a recombination reaction that is speciﬁc for
mutant LoxP sequences (Lee and Saito, 1998). Because the LoxP sites
are not identical, they also cannot recombine to excise the inserted
HIV proviral genome.
We ﬁrst reconstructed an HIV-1 proviral genome to contain the
LoxP sequence (5171) immediately preceding the 5′ LTR and also
downstream of the 3′ LTR (2272). This proviral genome pNLENGires
contains a gene encoding GFP positioned 5′ to the Nef reading frame
(Levy et al., 2004). GFP is expressed from the Nef mRNA due to an IRES
positioned between GFP and Nef (Levy et al., 2004). Since there were
no convenient restriction sites within the 5′ and 3′ LTRs and ﬂanking
regions, we ﬁrst constructed two separate transfer plasmids that were
used to insert the LoxP sequences upstream and downstream of the
LTRs. The ﬁrst transfer plasmid contained an HpaI to a NaeI deletion
from pNLENGires which eliminated the 3′ LTR region. A second
transfer plasmid was constructed in which a StuI digestion was used
to remove the 5′ LTR. Recombineering was then used to modify the
transfer plasmids to insert the LoxP sequences. For the 5′ LTR, DNA
oligonucleotides were designed to amplify from the RK6γ ori-Kan
gene sequence to include a restriction site for NotI at the 5′ end and
the sequence for LoxP(5171) at the 3′ end. For recombineering, an
additional 60 nucleotides of sequence complementarity with the
plasmid sequence in pNLENGires and with the 5′ LTR region (using
the transfer plasmid generated from the HpaI to NaeI deletion) was
used at the 5′ end. A similar design was used to construct the LoxP
(2272) 3′ of the 3′ LTR. DNA oligonucleotides were designed to
encode LoxP(2272) followed by the gene encoding chloramphenicol
resistance and a NotI restriction site. The oligos also included 60
nucleotides of complementarity for the 3′ LTR and 60 nucleotides of
complementarity for the plasmid sequence downstream of the 3′LTR
in the 3′ transfer plasmid.
For recombineering, E. coli containing either the plasmid contain-
ing the 5′ LTR or 3′ LTR were transformed with pSC101-BAD-gba and
selected for resistance to ampicillin (encoded on the transfer plasmid)
and tetracycline (encoded by pSC101-BAD-gba) at 30 °C. Colonies
were selected and mini-preparations DNA were done to ensure the
presence of both plasmids. Recombineering was done using standard
conditions (see last section) to induce the λ recombination proteins
under control of arabinose operon. The PCR products targeting the
LoxP to the 5′ LTR and transfer plasmid (consisting of NotI-Kan-RK6γ
ori-LoxP(5171)) and the PCR product targeting the 3′ LTR (consisting
of LoxP(2272)-Cm-NotI) were electroporated into the cells containing
the appropriate target transfer plasmid. Successfully recombineered
genomes were selected by ampicillin/kanamycin (5′ modiﬁcation)
and ampicillin/chloramphenicol (3′ modiﬁcation). The resulting
plasmids were characterized by restriction digest and DNA sequenc-
ing to conﬁrm the positioning of the LoxP(5171) immediately
preceding to the 5′ LTR and following the 3′ LTR (LoxP(2272)). A
NotI to BamHI digestion of both plasmids followed by ligation,
transformation, and selection on kanamycin/chloramphenicol
resulted in pNLENGires with LoxP(5171) preceding the 5′ LTR and
LoxP(2272) immediately following the 3′ LTR. This plasmid encodes
antibiotic resistance for kanamycin and chloramphenicol with an
origin of replication for RK6γ so that it will only replicate in E. coli
(pir+); the plasmid was renamed pHIV-LP.
To exchange HIV-LP for RPSL-LP in the BAC clone, we utilized a
plasmid encoding Cre recombinase, pCre, under control of the λ
temperature-sensitive promoter. For the exchange reaction, Cre was
co-transformed with pHIV-LP at a ratio of 1:10 into E. coli containing atarget BAC in electroporation. Following a 30-min recovery at 30 °C,
the cultures were shifted to 42 °C for 15 min to induce the expression
of Cre. Cultures were then incubated for an additional 30 min to 1 h at
35 °C with vigorous shaking. The E. coli was spread onto plates
containing chloramphenicol (to select for the BAC) and tetracycline
(to select for pCre). Colonies were allowed to grow at 30 °C for at least
24 h. The BACs that had undergone successful recombination with
HIV-LP were identiﬁed through replicate plating of the colonies onto
plates with chloramphenicol and kanamycin. Since the colonies with
(the un-recombined) RPSL-LP would grow on chloramphenicol and
chloramphenicol/kanamycin, those colonies that showed no growth
on the chloramphenicol/kanamycin colonies were selected for further
analysis. The identiﬁed colonies were grown in either liquid broth
containing chloramphenicol or chloramphenicol/kanamycin to con-
ﬁrm the loss of the RPSL gene. The successful insertion of HIV-LP into
the RPSL site was conﬁrmed using PCR speciﬁc for HIV. To conﬁrm the
complete loss of pCre, the colonies were also re-streaked onto plates
containing chloramphenicol and incubated at 37 °C for 24 h (since
pCre contains a temperature sensitive origin of replication). Individual
colonies were selected and tested for growth restriction in chloram-
phenicol/kanamycin, and PCR was used to reconﬁrm the presence of
HIV-LP. The overall frequency of recombination of HIV-LP into the BAC
clone varied with different BAC clones but usually was in the range of
0.5% to 1%.
PCR of 5′ and 3′ BAC–HIV
The BAC–HIVs were characterized using primers speciﬁc for HIV
and the surrounding 5′ and 3′ DNA of the target site (Table 1). PCR
reactions were used to amplify 500 bp upstream from the inserted 5′
LTR into the HIV genome. A second PCR product was generated for the
3′ LTR to 500 bp downstream from the insertion site. Both PCR
products were TA cloned, and the nucleotide sequence determined to
ensure that the HIV-LP was positioned at the desired site.
Analysis of BAC–HIV
The BAC–HIVs were characterized by Southern blots using
standard techniques (Sambrook and Russell, 2001). Brieﬂy, the
BAC–HIV DNAs were ﬁrst digested with SphI, which cuts one time in
the HIV genome. The restricted DNA was electrophoresed in a 0.8%
agarose gel followed by blotting under standard conditions. Following
pre-hybridization, the blot was incubated with an oligonucleotide
with a 5′ biotin that was complementary to nucleotides 762–784
(Kuiken et al., 2009) of the HIV genome (Table 1). Following washing,
the blot was developed with streptavidin phosphatase according to
the manufacturer's directions (Roche). The blot was then exposed to
X-ray ﬁlm.
Transfection of BAC–HIV
BAC–HIV was puriﬁed using standard alkalin lysis procedures
using phenol chloroform followed by choloroform isoamyl alcohol
and precipitation in ethanol. The DNA was re-dissolved overnight at
4 °C in water and the OD260 was determined. Transfection was
accomplished using FuGENE (Roche) at a ratio of 3:2 of FuGENE to
DNA. Usually 2–5 μg of BAC was used for each transfection (1 μg for
HIV-LP), which was determined in preliminary experiments to be the
optimum for production of infectious HIV. The 293 T cells were plated
at 5 × 105 cells per well of a 6-well plate a day prior to transfection.
Analysis of infectious HIV
At 72 h after transfection of 293 T cells, the media was removed,
centrifuged to remove any cell debris, and placed onto 6-wells of JC-53
cells that had been previously seeded the day before (Moore-Rigdon
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the presence of β-galactosidase. Counting of the β-galactosidase-positive
cells was done using a light phase microscope with the numbers of
β-galactosidase-positive cells reported as infectious units per ml of
culture.
For FACs analysis of 293 T cell colonies, the cells were either left
unstimulated or stimulated with TNF-α (10 ng/ml) for 72 h. The cells
were harvested and sorted for GFP.
Selection of 293 T cell lines with integrated BAC–HIV
To generate cell lines, BAC–HIVs or BAC–RPSLs were constructed
with pIRES-puro (Clontech). For each co-transfection, we maintained
the BAC–HIV or BAC–RPSL at a constant amount and combined with
descending dilution of pIRES-puro. After 72 h of transfection with
FuGENE6, the cells were isolated and replicated into 100 mM dishes
with puromycin at 2 μg/ml. After 1–2 weeks, visible, well-separated
colonies of cells were isolated with cloning cylinders (Milipore) and
expanded. Cell colonies containing BAC–HIV or BAC–RPSL were
identiﬁed by isolation of chromosomal DNA and PCR with primers
speciﬁc for HIV or RPSL.
Analysis of 293 T cell chromosomal DNA for BAC–HIV or BAC–RPSL
The 293 T cells were processed to extract high molecular weight
genomic DNA as previously described (Moore-Rigdon et al., 2005). To
detect HIV DNA, three primer sets were used that encompassed the
primer-binding site (PBS), Gag and Nef genes (Table 1). PCR primers
speciﬁc for the RPSL genes were used to detect 293 T cell lines
containing BAC–RPSL.
PCR of 5′ and 3′ regions using the same primers was performed
with chromosomal DNA from BAC–HIV colonies to conﬁrm the
integrity of the BAC–HIV following transfection.
PCR was used to contain the presence of the host promoter of
BAC–Top2A and BAC–DNMT cell clones. The primers used for the host
cell promoters and listed in Table 1 andwere used in conjunctionwith
the HIV 5′ primer used to PCR the 500 bp of the BAC upstream of the
integration site. The conditions for PCR were as per manufacturer's
instructions for long-amp PCR (New England Biolabs). All PCR
products were electrophoresed in 0.8% agarose and visualized with
ethidium bromide staining.
Real-time PCR quantitation assay (qPCR)
A real-time PCR quantitation assay was used to quantitate HIV-1
DNA copy number in cultured cells. PCR primers and a ﬂuorescent
TaqMan probewere design to amplify and detect a 128 bp fragment in
the gag p24 region for NL4.3. Brieﬂy, 2 μl of extracted genomic DNA
was mixed in a total volume of 20 μl TaqMan reactions containing 1×
ABsoluteTM Fast QPCR Low ROX mix (2×) (Thermo Fisher Scientiﬁc),
200 nM forward primer SGG-F 5′-TCAAGCAGCCATGCAAATGTTAAA-3′
(HXB2 nucleotide position 1371–1394), 200 nm reverse primer SGG-
R 5′-CTATGTCACTTCCCCTTGGTTCT-3′ (HXB2 1476–1498), 200 nm
TaqMan probe GGS1 5′-(FAM) TCTATCCCATTCTGCAGCTTCCTCATT-
GAT (BHQ1)-3′ (HXB2 1402–1431) coupled with a reporter dye
[6-carboxy ﬂuorescein (FAM)] at the 5′-end and a non-ﬂuorescent
quencher [Black Hole Quenchere Dye (BHQ1)] at the 3′-end (Operon
Euroﬁns). Experimental samples were ran in duplicate wells in
conjunction with eight negative control wells with no DNA template,
and plasmid DNA standards, using a Fast optical 96-well reaction plate
(Applied Biosystems).
Reactions were then performed in a 7900HT Fast Real-Time PCR
System (Applied Biosystems) using the following PCR conditions: one
initial thermal step at 95 °C for 5 min (to activate the Thermo-Fast
DNA polymerase), followed by 40 cycles of two-step PCR: 95 °C for
15 s (for DNA denaturation) and at 60 °C for 45 s (for annealing andextension). A hot start at the initial heating step prevents non-speciﬁc
ampliﬁcation during the reaction setup. At the end of the run, data
were analyzed using the ampliﬁcation plots and other tools contained
in the System Detection System software of the instrument.
The standard curve was generated with plasmid DNA containing
the HIV-1 target sequence pHRV1 and kept frozen at −80 °C in
multiple aliquots. For each run, an aliquot of the plasmid was ﬁvefold
serially diluted in duplicate wells (400,000, 80,000, 16,000, 3200, 640,
128, 25.6, 5.1 copies per reaction). Copy number in the plasmid DNA
standard stock was calculated by its size (total number of base pairs)
and DNA concentration by spectrophotometry; in addition, calculated
copy number was validated with a Poisson distribution analysis by
amplifying a highly diluted plasmid aliquot (0.3 copies per reaction in
a 96-well microplate), such that after 40 cycles of PCR ampliﬁcation, a
large fraction of wells (N70%) have ﬂuorescence intensities below the
threshold level (PCR negative). The sensitivity, linearity, precision,
and accuracy of the assay were determined using this plasmid DNA
standard, genomic DNA derived from cell lines containing a single
HIV-1 copy per cell, as well as peripheral blood mononuclear cell DNA
from HIV-infected and uninfected subjects, and found to detect a
single HIV DNA copy per reaction (Salazar-Gonzalez, unpublished).
The HIV-1 genome number per human cell-equivalent was
calculated based on the HIV copy number obtained by the TaqMan
assay, divided by the input equivalent cell number per reaction. The
human genomic DNA content was obtained spectrophotometrically
for each genomic DNA extract. Since there is an estimated
3,000,000,000 bp per human haploid genome, we calculated the
mass DNA per human cell-equivalent to be 3.3 pg (Salazar-Gonzalez,
unpublished).
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